CIRM Funded Clinical Trials

Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis

Kristen Johnson
CIRM Grant:
CLIN2-10388 (Closed)
Award Value:
Trial Sponsor:
Trial Stage: 
Phase 1
Trial Status: 
Targeted Enrollment:
60 ID:

Researchers at the California Institute for Biomedical Research (CALIBR) have been awarded $8.447 million to test KA34, a drug that, in preclinical tests, recruits stem cells to create new cartilage in areas damaged by osteoarthritis. CIRM funded the research that developed this technology and now this Phase 1 trial will test this stem cell directed treatment in people with osteoarthritis of the knee, hopefully slowing down or even halting the progression of the disease. 


A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study.


This study will evaluate the safety and tolerability of KA34 when administered to patients with osteoarthritis of the knee.